Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited (the "Stock Exchange") take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

# **Ritamix Global Limited**

利特米有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1936)

## UPDATE ON EXPECTED TIMELINE FOR USE OF PROCEEDS

References are made to (i) the announcement of Ritamix Global Limited (the "**Company**", together with its subsidiaries, the "**Group**") dated 27 September 2023 in relation to the update on the expected timeline for use of proceeds (the "**Announcement**"); and (ii) the interim report of the Company for the six months ended 30 June 2024 published on the 27 September 2024. Unless otherwise defined, capitalised terms used in this announcement shall have the same meaning as those defined in the Announcement.

# USE OF NET PROCEEDS AND PREVIOUS UPDATE ON EXPECTED TIMELINE FOR USE OF NET PROCEED

The net proceeds received by the Company from the Listing amounted to approximately HK\$72.4 million, after deducting the underwriting fees, commissions, and other listing expenses (the "**Net Proceeds**"). Up to 30 June 2024, the unutilised Net Proceeds were approximately HK\$57.7 million (the "**Unutilised Net Proceeds**").

According to the 2022 Annual Report, the Board has resolved to revise the expected timeline for the use of Net Proceeds (the "**1st Timeline Revision**"). On 27 September 2023, the Board resolved to further extend the expected timeline for the use of Net Proceeds (the "**2nd Timeline Revision**").

# FURTHER REVISION TO THE EXPECTED TIMELINE FOR THE USE OF UNUTILISED NET PROCEEDS

On 27 December 2024, the Board resolved to further extend the timeline for the use of the Unutilised Net Proceeds (the "**3rd Timeline Revision**").

The allocation of the Net Proceeds following the change of use in Net Proceeds as per the 2021 UOP Announcement, the status of the utilisation of Net Proceeds during the period from the Listing Date and up to 30 June 2024 (the "**Relevant Period**"), the expected timeline to use the Net Proceeds following the 1st Timeline Revision, the 2nd Timeline Revision, and the 3rd Timeline Revision are as follows:

	Planned	Actual use of the Net Proceeds during the	Unutilised	Expected timeline to use the Net Proceeds	Expected timeline to use the Net Proceeds	Expected timeline to use the Net Proceeds
	use of the Net Proceeds HK\$' million	Relevant Period HK\$' million	amount at 30 June 2024 HK\$' million	(as per the 1st Timeline Revision)	(as per the 2nd Timeline Revision)	(as per the 3rd Timeline Revision)
Construct a new manufacturing plant Funding potential investment in a company that is engaged in animal feed additives and/or	42.1	_	42.1	30 June 2024	31 December 2025	31 December 2026
veterinary-related industry	13.4	7.8	5.6	31 December 2023	31 December 2025	31 December 2026
Conduct sales and marketing activities	1.7	0.9	0.8	30 June 2024	31 December 2024	31 December 2025
Set up a new testing laboratory	3.5	—	3.5	30 June 2024	31 December 2025	31 December 2026
Set up a centralised Enterprise Resources Planning system	3.7	_	3.7	31 December 2023	31 December 2025	31 December 2026
Hire additional workforce	3.0	1.0	2.0	31 December 2023	31 December 2025	31 December 2026
Purchase trucks for logistics services					NT	NT
and vehicles for sales personnel General working capital	1.4 <u>3.6</u>	1.4		Not applicable Not applicable	Not applicable Not applicable	Not applicable Not applicable
TOTAL	72.4	14.7	57.7			

#### Construct a new manufacturing plant

Approximately HK\$42.1 million of the Unutilised Net Proceeds allocated for constructing a new manufacturing plant remains unutilised by the Group. Since 2020, the COVID-19 pandemic has adversely impacted the global economy. Several of the Group's key customers have slowed down their planned business expansion activities, amongst others, including the acquisitions of poultry farms and the increase in broiler production capacity. Consequently, the Group experienced delays in securing previously forecasted additional orders from these existing customers.

Moreover, the disruption to supply chains caused by COVID-19 has led to shortages of shipping containers and negatively affected the Group's overseas sales due to logistical challenges. Additionally, outbreaks of animal diseases such as avian influenza (H5N1) and African Swine Fever in several regions where the Group's brand of animal feed additives and premixes are sold have further exacerbated the situation.

The industry and Group continue to face intense competition locally and from China as a result of a slower-than-expected recovery from the African Swine Fever. This has further reduced the Group's production and delayed plans for constructing a new manufacturing plant. In response to such

circumstances, the Group adopted a cautious approach to further assess market demand for its animal feed additives premixes before increasing its production capacity and expanding its product portfolio. It is expected that the unutilised proceeds will be fully utilised on or before 31 December 2026.

# Funding potential investment in a company that is engaged in animal feed additives and/or veterinary related industry

Approximately HK\$5.6 million of the Unutilised Net Proceeds allocated for funding potential investment in a company that is engaged in animal feed additives and/or veterinary-related industry remains unutilised by the Group.

The Group has remained prudent in its investment in light of the effects of the COVID-19 pandemic and the challenges in this industry due to the African Swine Fever outbreak. As a result, the Group has not been able to identify any potential investment that meets its criteria and will continue to seek suitable investment opportunities. It is expected that the unutilised proceeds will be fully utilised on or before 31 December 2026.

## **Conduct sales and marketing activities**

Approximately HK\$0.8 million of the Unutilised Net Proceeds allocated for conducting sales and marketing activities remains unutilised by the Group. The Group was unable to (i) participate in domestic and international fairs and exhibitions; (ii) visit existing and potential suppliers and customers; and (iii) conduct in-person training, seminars, and workshops for our sales and technical team during the travel restrictions imposed to combat the COVID-19 outbreak, which delayed the utilisation of the Net Proceeds.

The Group recognises the importance of effective sales and marketing activities. Since the beginning of 2024, their sales and marketing team visited several existing and potential suppliers and customers which utilised part of the Net Proceeds. In addition, the Group has identified and planned to attend several international trade events and exhibitions and conduct in-person training, seminars, and workshops for their sales and technical team in 2025. The timeline for utilising the unutilised proceeds has been further extended to 31 December 2025.

## Set up a new testing laboratory

Approximately HK\$3.5 million of the Unutilised Net Proceeds allocated for setting up a new testing laboratory remains unutilised by the Group. Setting up a new laboratory would enable the Group to provide complementary laboratory testing services to customers. The Group has also decided to construct a new testing laboratory within the new manufacturing plant. As a result, the timeline has been extended in line with the construction of a new manufacturing plant to 31 December 2026.

## Set up a centralised Enterprise Resources Planning ("ERP") system

Approximately HK\$3.7 million of the Unutilised Net Proceeds allocated for setting up a centralised ERP system remains unutilised by the Group. The Group believes having a centralised ERP system will enhance operational efficiency, improve management of decentralised locations, support higher production capacity, and drive revenue growth in the future. The delay in constructing a new manufacturing plant has lessened the immediate need for a centralised ERP system.

The Group plans to set up the centralised ERP system once the new manufacturing plant is constructed, the unutilised proceeds will be fully utilised on or before 31 December 2026.

#### Hire additional workforce

Approximately HK\$2.0 million of the Unutilised Net Proceeds allocated for hiring additional workforce remains unutilised by the Group. Delays in the construction of the new manufacturing plant and the set up of the new testing laboratory have postponed the Group's hiring plan for additional workforce on both sides.

The Group plans to proceed with recruitment once the expansion plans for the new manufacturing plant and the new testing laboratory are finalised and when market demand shows signs of improvement. The unutilised proceeds will be fully utilised on or before 31 December 2026.

#### **REASONS FOR EXTENDING THE EXPECTED TIMELINE FOR THE USE OF PROCEEDS**

The expected timeline to use the Net Proceeds is based on the Directors' best estimation after due and careful consideration of the latest developments of the Group, barring any unforeseen circumstances, and it may be subject to change based on the market conditions. The Board considers that the 3rd Timeline Revision would allow the Group to allocate its financial resources more efficiently. This revision is deemed to be in the best interest of the Company and its Shareholders as a whole and is not expected to have any material adverse effect on the existing business and operations of the Group. Except as disclosed in this announcement, there are no other changes to the use of Net Proceeds.

In the event of any material change in the intended use of the Unutilised Net Proceeds and/or the 3rd Timeline Revision, the Company will make appropriate announcement(s) in due course.

For and on behalf **Ritamix Global Limited Dato'Sri Lee Haw Yih** *Chairman and Executive Director* 

#### Malaysia, 27 December 2024

As of the date of this announcement, the executive Directors are Dato'Sri Lee Haw Yih and Datin Sri Yaw Sook Kean; the non-executive Director is Mr. Lee Haw Shyang; and the independent non-executive Directors are Ms. Ng Siok Hui, Mr. Lim Chee Hoong and Ms. Tee Pao Hwei.